Just listened. The only comment I heard was on Rindo in that the combo trial with Avastin could lead to a faster path to approval. No timeline, but it would certainly not be in 2012.
The trial is a randomized P2 in recurrent glioblastoma. I assume that he is saying that in this setting there is more of an unmet need, thus the FDA could accept this P2 data for (accelerated?) approval.